1 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Fusion Pharma LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene PF-114 - Chronic Myeloid Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 1 / Phase 2 | Unknown | Fusion Pharma LLC | 65 | 2016-07-01 | 2020-02-17 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Chronic-Phase (1)
PF-114 (1)
Russia (1)